Base editing is named as an advanced CRISPR technology enabling targeted modification relevant to cereal crop traits.
First-pass extracted concept
base editing
Candidate: concept label4 source documents6 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
Evidence Snippets
Recent advances in CRISPR technologies, including Cas9, Cas12, Cas13, base editing, and prime editing, have enabled targeted modification of genes and regulatory elements controlling yield, stress tolerance, and grain nutritional quality in major cereals such as rice, wheat, maize, and barley.
This review covers the various editing tools and strategies used for precise gene editing in hemophilia, including approaches such as HDR, NHEJ, base editing, prime editing, ex vivo gene editing in iPSCs, and recent LNP-based CRISPR delivery methods for precise editing.
Emerging technologies-base/prime editing, hybrid nucleases, and rigorous monitoring-promise enhanced precision and safety.
Additionally, genome editing technologies, including CRISPR/Cas9-mediated nonhomologous end joining, base editing, and prime editing, offer variant-specific therapeutic potential.
Supporting Sources
Linked Claims
Cas9, Cas12, Cas13, base editing, and prime editing have enabled targeted modification of genes and regulatory elements controlling yield, stress tolerance, and grain nutritional quality in rice, wheat, maize, and barley.
Quoted textsource-backed
Recent advances in CRISPR technologies, including Cas9, Cas12, Cas13, base editing, and prime editing, have enabled targeted modification of genes and regulatory elements controlling yield, stress tolerance, and grain nutritional quality in major cereals such as rice, wheat, maize, and barley.
The source reviews hemophilia gene-editing strategies including HDR, NHEJ, base editing, prime editing, ex vivo iPSC editing, and LNP-based CRISPR delivery methods.
Quoted textsource-backed
This review covers the various editing tools and strategies used for precise gene editing in hemophilia, including approaches such as HDR, NHEJ, base editing, prime editing, ex vivo gene editing in iPSCs, and recent LNP-based CRISPR delivery methods for precise editing.
Gene editing for hemophilia is presented as an emerging approach that aims to provide a permanent cure by precise correction of the mutated gene or targeted integration of coagulation factor cDNA for stable expression.
Quoted textsource-backed
Gene editing for hemophilia is an emerging approach that aims to provide a permanent cure by editing the mutated gene precisely or targeted integration of coagulation factor cDNA into the host genome for stable expression.
Key remaining challenges for hereditary hearing loss gene therapy include expanding the therapeutic window, ensuring long-term safety, and establishing ethical and regulatory frameworks.
Quoted textsource-backed
Despite these advances, challenges remain in expanding the therapeutic window, ensuring long-term safety, and establishing ethical and regulatory frameworks for their use.
Base editing, prime editing, hybrid nucleases, and rigorous monitoring are presented as emerging technologies that may enhance precision and safety.
Quoted textsource-backed
Emerging technologies-base/prime editing, hybrid nucleases, and rigorous monitoring-promise enhanced precision and safety.
CRISPR/Cas9-mediated nonhomologous end joining, base editing, and prime editing offer variant-specific therapeutic potential for hereditary hearing loss.
Quoted textsource-backed
Additionally, genome editing technologies, including CRISPR/Cas9-mediated nonhomologous end joining, base editing, and prime editing, offer variant-specific therapeutic potential.